Company Analysis
Sign in

Scinai Immunotherapeutics Ltd. (SCNI)

Nasdaq: SCNI · Biological Products, (No Diagnostic Substances) · Jerusalem, IL · filing with the SEC since 2014
Full chart Alerts Compare
Grade3.9
◀ Past 3.5● Present 3.8▶ Future 4.3
5 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue$1.3M+99.2%
Net income-$8.3M-273.2%
Earnings per sharen/a
Operating cash flow-$6.0M+4.8%
Cash$1.8M-13.6%
Debtn/a
Shareholders’ equity$8.1M-18.8%
Shares, diluted9.34B+189.6%
Return on equity-102.5%
The recordfrom its filings
Filings in 202645
Newest filingNov 10 · 424B3
Annual reportApr 1, 2026
Quarterly reportMay 15, 2023
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted4
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
2122232425
As filed, in USD. Nothing here is a forecast.

News

Nov 10, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Nov 9, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Oct 5, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton SCNI · research, not advice